A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

NCT06703268 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: HSK7653 10 mg
DRUG: Daily DPP-4 inhibitor

Sponsor

Haisco Pharmaceutical Group Co., Ltd.